Affymetrix Named One of the World's Top 50 Innovative Companies
March 06 2008 - 4:05PM
Business Wire
Affymetrix Inc. (Nasdaq:AFFX) today announced that it has been
named as one of the world�s top 50 most innovative companies by
Fast Company magazine, a prominent monthly publication with a
worldwide circulation in excess of 730,000 that focuses on new
business practices and individuals who are reinventing business.
Affymetrix was the only life sciences company to be recognized in
the 2008 Fast 50: The World�s 50 Most Innovative Companies annual
poll, published in the March 2008 issue of Fast Company. The
company was commended for its work relating to the discovery of
genetic variations and drug metabolism. Ranked 13th, Affymetrix
sits alongside innovation giants and mainstream brands such as
Google, Apple, Nike, Facebook, Nokia and Nintendo. To view the
Affymetrix listing, please visit:
http://www.fastcompany.com/multimedia/slideshows/content/
fast50_08.html?page=38 (Due to its length, this URL may need to be
copied/pasted into your Internet browser's address field. Remove
the extra space if one exists.) In preparing the annual poll, Fast
Company�s editors and researchers spoke to numerous experts and
conducted a detailed analysis of each company�s financial
information and products. According to the publication, the
featured companies are �pushing business to new places and taking
chances beyond what is expected, proving beyond doubt that business
is a force for change.� �We consulted dozens of our contributors
around the world who took nominations from experts and business
leaders in every industry,� said Tom Foster, editor of the 2008
Fast 50. �We didn�t look only at small companies or only at major
conglomerates � we considered any company whose innovations in the
past year have proven game-changing in their fields. That meant
looking at everything from how they treat their employees to how
they manage their supply chains to, of course, their most dazzling
new products. In the end, a panel of Fast Company editors and
writers voted on more than 300 finalists to come up with the
ultimate list of 50. Affymetrix stood out not only because it�s
part of a hot field with tremendous possibility, but also because
so much of that possibility is already being realized.� �This
recognition by Fast Company is a great achievement for Affymetrix
and a direct reflection of our tremendous depth of talent,� said
Kevin King, President of Affymetrix. �Looking to the future, we�re
intensely committed to maintaining our leadership position with new
innovations that will continue to accelerate genetic discoveries
and transform the future of patient care and treatment. In fact,
customers are now using our recently released DMET solution to
better understand an individual�s response to different drugs like
warfarin1, which will ultimately help improve the drug dosing
dilemma and reduce the risks of adverse reactions.� About
Affymetrix Affymetrix GeneChip� microarray technology is the
industry-standard tool for analyzing complex genetic information.
After inventing microarray technology in the late 1980s, Affymetrix
scientists have been dedicated to developing innovative products
that provide researchers with a more complete view of the genome.
These products continue to accelerate genetic research and enable
scientists to develop diagnostics and tailor treatments for
individual patients by identifying and measuring the genetic
information associated with complex diseases. Today, Affymetrix
technology is used by the world�s top pharmaceutical, diagnostic
and biotechnology companies, as well as leading academic,
government and not-for-profit research institutes. More than 1,700
systems have been shipped around the world and more than 11,000
peer-reviewed papers have been published using the technology.
Affymetrix is headquartered in Santa Clara, Calif., and has
manufacturing facilities in Sacramento, Calif., Cleveland, Ohio,
and Singapore. The company has about 1,100 employees worldwide and
maintains sales and distribution operations across Europe and Asia.
For more information about Affymetrix, please visit:
www.affymetrix.com. Forward-looking Statements All statements in
this press release that are not historical are �forward-looking
statements� within the meaning of Section 21E of the Securities
Exchange Act as amended, including statements regarding Affymetrix�
�expectations,� �beliefs,� �hopes,� �intentions,� �strategies� or
the like. Such statements are subject to risks and uncertainties
that could cause actual results to differ materially for Affymetrix
from those projected, including, but not limited to: risks and
uncertainties relating to Affymetrix� ranking in Fast Company�s
�2008 Fast 50: The World�s 50 Most Innovative Companies,� discussed
in this press release; risks of the company�s ability to achieve
and sustain higher levels of revenue, higher gross margins and
reduced operating expenses; uncertainties related to technological
approaches, manufacturing and product development; personnel
retention; uncertainties related to cost and pricing of Affymetrix
products; dependence on collaborative partners; uncertainties
related to sole-source suppliers; risks associated with past and
future acquisitions; uncertainties relating to FDA and other
regulatory approvals; competition; risks relating to intellectual
property of others and the uncertainties of patent protection and
litigation. These and other risk factors are discussed in
Affymetrix� Form 10-K for the year ended December 31, 2006, and
other SEC reports, including its Quarterly Reports on Form 10-Q for
subsequent quarterly periods. Affymetrix expressly disclaims any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in Affymetrix� expectations with regard thereto
or any change in events, conditions or circumstances on which any
such statements are based. NOTE: Affymetrix, the Affymetrix logo
and GeneChip� are registered trademarks owned or used by Affymetrix
Inc. 1
http://investor.affymetrix.com/phoenix.zhtml?c=116408&p=irol-news
Article&ID=1105493 (Due to its length, this URL may need to be
copied/pasted into your Internet browser's address field. Remove
the extra space if one exists.)
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2023 to Sep 2024